The Economic Times  May 21  Comment 
Natco Pharma has received environment clearance (EC) for its Rs 480 crore expansion project in Telangana that would generate 1,500 jobs.
The Hindu Business Line  May 16  Comment 
Shares of Natco Pharma jumped on hike in foreign investment limit. The stock rose as much as 3.07 per cent to Rs 963, highest since April 20. The Reserve Bank of India (RBI) has allowed Foreign I...
The Economic Times  May 15  Comment 
Foreign Institutional Investors (FIIs)/Foreign Portfolios Investors (FPIs) can now invest from 31.50 per cent to 49 per cent of the paid up capital.
The Hindu Business Line  May 10  Comment 
Natco Pharma has launched generic version of pomalidomide capsules for treatment of blood cancer in the domestic market.Pomalidomide is sold by Celgene Inc in the US under the brand Pomalyst. The Hyde...
The Hindu Business Line  May 8  Comment 
Laurus Labs has informed the stock exchanges that its pharmaceutical formulations and marketing partner Natco Pharma has launched the generic version of Sofosbuvir 400 mg/Velpatasvir 100 mg fixed dos...
The Hindu Business Line  Mar 21  Comment 
Natco Pharma and the University of Hyderabad (UoH) have signed an MoU to carry out advance research in the areas of pharmaceutical importance. The focus areas will be discovery of novel drugs, dev...
The Hindu Business Line  Mar 21  Comment 
The Hindu Business Line  Mar 8  Comment 
In a significant ruling for generic drug companies, the Delhi High Court has allowed Hyderabad-based Natco to export its version of Bayer’s patented drug sorafenib tosylate for experimental purposes.
The Economic Times  Feb 28  Comment 
The report says that while there is room for a Blue Sky scenario in NPL once again, a probability discussed later in this report, it is not enough to assign a Buy rating to the stock.
The Economic Times  Feb 14  Comment 
Consolidated total income from operations rose to Rs 679.01 crore for the quarter as against Rs 288.09 crore a year ago.
The Economic Times  Feb 1  Comment 
“The share price fairly reflects upside from Copaxone 40 mg and approval remains a hurdle,“ said Nimish Mehta, founder director at ResearchDelta Advisors.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki